STOCK TITAN

Hemogenyx Pharmaceuticals Plc - HOPHF STOCK NEWS

Welcome to our dedicated news page for Hemogenyx Pharmaceuticals Plc (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharmaceuticals Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Hemogenyx Pharmaceuticals Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Hemogenyx Pharmaceuticals Plc's position in the market.

Rhea-AI Summary
Hemogenyx Pharmaceuticals (HEMO) announces promising results for the potential use of its Chimeric Bait Receptor platform in the treatment of Non-Hodgkin Lymphoma (NHL) and solid tumors. The company's AI-based protein structure simulations and in-house mRNA synthesis have accelerated R&D efforts, showing potential for treating relapsed and/or refractory stage III/IV metastasized NHL and solid tumors like epithelial ovarian cancer and certain carcinomas. Preliminary tests against live infectious SARS-CoV-2 also show promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc (LSE:HEMO) has successfully completed the re-manufacturing of an improved lentivirus devoid of splice variants, essential for the development of their HEMO-CAR-T cells to treat acute myeloid leukaemia. The re-manufacturing resolves the clinical hold imposed by the FDA, allowing the company to move forward with the IND application and subsequent clinical trials. CEO Dr Vladislav Sandler expressed optimism about the clear path to lifting the clinical hold and the company's commitment to expeditiously resubmit the IND.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals plc announces that the total issued share capital of the Company consists of 1,153,065,988 ordinary shares. None of the shares are held in treasury. The total number of voting rights in the Company is 1,153,065,988.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals. Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals receives FDA acceptance of plan to address concerns on HEMO-CAR-T IND application
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Hemogenyx Pharmaceuticals announces publication of patent application for chimeric bait receptors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Hemogenyx Pharmaceuticals Plc

OTC:HOPHF

HOPHF Rankings

HOPHF Stock Data

53.67M
1.03B
10.73%
0.83%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
50 Jermyn Street